Last reviewed · How we verify
placebo and tramadol — Competitive Intelligence Brief
marketed
Opioid analgesic with monoamine reuptake inhibition
Mu-opioid receptor; norepinephrine transporter; serotonin transporter
Pain Management
Small molecule
Live · refreshed every 30 min
Target snapshot
placebo and tramadol (placebo and tramadol) — University of Southern Denmark. Tramadol is a synthetic opioid analgesic that inhibits reuptake of norepinephrine and serotonin while also acting as a weak mu-opioid receptor agonist to provide pain relief.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| placebo and tramadol TARGET | placebo and tramadol | University of Southern Denmark | marketed | Opioid analgesic with monoamine reuptake inhibition | Mu-opioid receptor; norepinephrine transporter; serotonin transporter | |
| Tramadol HCl/acetaminophen Extended Release | Tramadol HCl/acetaminophen Extended Release | Janssen Korea, Ltd., Korea | marketed | Opioid analgesic combination with NSAID alternative | Mu-opioid receptor; norepinephrine transporter; serotonin transporter | |
| Tramadol hydrochloride/ Acetaminophen | Tramadol hydrochloride/ Acetaminophen | Janssen Korea, Ltd., Korea | marketed | Opioid analgesic combination | Mu-opioid receptor; norepinephrine transporter; serotonin transporter | |
| Tramadol hydrochloride/Acetaminophen Tab. | Tramadol hydrochloride/Acetaminophen Tab. | Daewon Pharmaceutical Co., Ltd. | phase 3 | Opioid analgesic combination | Mu-opioid receptor; norepinephrine transporter; serotonin transporter | |
| Tramadol IV (Tradonal® IV) | Tramadol IV (Tradonal® IV) | University Hospital, Ghent | marketed | Opioid analgesic with monoamine reuptake inhibition | Mu opioid receptor; norepinephrine transporter; serotonin transporter | |
| Tramadol HCl | Tramadol HCl | Labopharm Inc. | marketed | Synthetic opioid analgesic with monoamine reuptake inhibition | Mu opioid receptor; norepinephrine transporter; serotonin transporter | |
| Tramadol 5% | Tramadol 5% | Al-Azhar University | phase 3 | Opioid analgesic with monoamine reuptake inhibition | Mu opioid receptor; norepinephrine and serotonin transporters |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Opioid analgesic with monoamine reuptake inhibition class)
- Al-Azhar University · 1 drug in this class
- Pfizer · 1 drug in this class
- University Hospital, Ghent · 1 drug in this class
- University of Southern Denmark · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- placebo and tramadol CI watch — RSS
- placebo and tramadol CI watch — Atom
- placebo and tramadol CI watch — JSON
- placebo and tramadol alone — RSS
- Whole Opioid analgesic with monoamine reuptake inhibition class — RSS
Cite this brief
Drug Landscape (2026). placebo and tramadol — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-and-tramadol. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab